PMID- 35023360
OWN - NLM
STAT- MEDLINE
DCOM- 20220404
LR  - 20220405
IS  - 1744-8301 (Electronic)
IS  - 1479-6694 (Linking)
VI  - 18
IP  - 11
DP  - 2022 Apr
TI  - Outcomes of sorafenib treatment of advanced renal cell carcinoma according to 
      IMDC risk criteria: analysis of Japanese real-world data from postmarketing 
      all-patient surveillance of sorafenib.
PG  - 1371-1380
LID - 10.2217/fon-2021-1001 [doi]
AB  - Aim: To assess sorafenib survival outcomes in renal cell carcinoma patients using 
      standard International Metastatic Renal Cell Carcinoma Data Consortium (IMDC) 
      risk criteria. Patients & methods: The authors restratified a real-world cohort 
      of 3255 advanced renal cell carcinoma patients, obtained from Japanese sorafenib 
      postmarketing surveillance, to assess survival outcomes using IMDC criteria; 
      intermediate risk was subdivided into intermediate 1 (Int-1) and imterdemiate 2 
      (Int-2; one and two risk factors, respectively). Results: Overall, 2225 (68%) 
      IMDC-evaluable patients were reclassified as favorable (17%), intermediate (62%) 
      and poor (21%) risk, with median progression-free survival of 10.4, 8.1 and 
      3.4 months, respectively. Int-1 (36%) and Int-2 (26%) subgroups had median 
      progression-free survival of 10.1 and 6.0 months, respectively. Sorafenib had 
      acceptable safety/tolerability. Conclusion: Sorafenib effectiveness was promising 
      for IMDC intermediate risk, particularly Int-1, warranting further investigation.
FAU - Inamoto, Teruo
AU  - Inamoto T
AD  - Department of Urology, Osaka Medical & Pharmaceutical University, Osaka, 
      569-8686, Japan.
FAU - Azuma, Haruhito
AU  - Azuma H
AD  - Department of Urology, Osaka Medical & Pharmaceutical University, Osaka, 
      569-8686, Japan.
FAU - Adachi, Masatoshi
AU  - Adachi M
AD  - Medical Affairs GU Oncology, Bayer Yakuhin Ltd, Osaka, 530-0001, Japan.
FAU - Okayama, Yutaka
AU  - Okayama Y
AD  - PMS, Pharmacovigilance Monitoring & Governance, Bayer Yakuhin Ltd, Osaka, 
      530-0001, Japan.
FAU - Sunaya, Toshiyuki
AU  - Sunaya T
AD  - Statistics & Data Insights, Research & Development Japan, Bayer Yakuhin Ltd, 
      Osaka, 530-0001, Japan.
FAU - Oya, Mototsugu
AU  - Oya M
AD  - Department of Urology, Keio University School of Medicine, Tokyo, 160-8582, 
      Japan.
LA  - eng
GR  - Bayer Yakuhin Ltd/
PT  - Journal Article
DEP - 20220113
PL  - England
TA  - Future Oncol
JT  - Future oncology (London, England)
JID - 101256629
RN  - 9ZOQ3TZI87 (Sorafenib)
SB  - IM
MH  - *Carcinoma, Renal Cell
MH  - Humans
MH  - Japan
MH  - *Kidney Neoplasms/pathology
MH  - Retrospective Studies
MH  - Sorafenib/therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - intermediate risk
OT  - kidney cancer
OT  - risk stratification
OT  - targeted therapy
OT  - tyrosine kinase inhibitor
EDAT- 2022/01/14 06:00
MHDA- 2022/04/05 06:00
CRDT- 2022/01/13 08:40
PHST- 2022/01/14 06:00 [pubmed]
PHST- 2022/04/05 06:00 [medline]
PHST- 2022/01/13 08:40 [entrez]
AID - 10.2217/fon-2021-1001 [doi]
PST - ppublish
SO  - Future Oncol. 2022 Apr;18(11):1371-1380. doi: 10.2217/fon-2021-1001. Epub 2022 
      Jan 13.